Cardiology is booming with innovation, but there’s one aspect that remains overlooked: who qualifies for minimally invasive therapies.
Cardiology should be “more aggressive about broadening who we’re targeting to care for,” Mark Ricciardi, MD, section chief for interventional cardiology and structural heart disease at Warrenville, Ill.-based Endeavor Health, said in an upcoming Becker’s “Cardiology + Heart Surgery Podcast.”
“While we’re experiencing an incredible boom in innovation for new device therapies, many of these therapies have been studied and introduced into clinical care as really niche therapies — just for really high-risk and frail patients who couldn’t otherwise withstand, say, open-heart surgery to treat their valve,” he said. “In my opinion, a true patient-centered approach to minimally invasive therapies shouldn’t be beholden to an open-heart surgical precedent, but should look to expand the application of these ingenious therapies to a broader patient population — not just those at the end of their rope.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
